Shares of Sangamo Therapeutics Inc. (SGMO) are down nearly 33% from their 52-week high to $18. Given the fact that the Company has potential clinical data readouts from 7 studies beginning in late summer of this year to 2019, it is worth keeping an eye on this stock.
from RTT - Biotech https://ift.tt/2trGwJt
via IFTTT
No comments:
Post a Comment